Phathom Pharmaceuticals Inc
Research Phathom Pharmaceuticals Inc (PHAT) on Bullrun: market cap USD 704.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHAT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 704.62M
- Financial periodQ2 2026
- RevenueUSD 74.27M
- Net income-USD 17.58M
- Free cash flow-USD 1.97M
- Gross margin79.7%
Valuation Snapshot
latest market cap is USD 704.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 175.11M | -USD 221.25K | -USD 167.00M | 87.1% | -3.03 | USD 129.97M | USD 209.09M | -USD 438.17M |
| FY2024 | USD 55.25M | -USD 334.33K | -USD 266.91M | 85.6% | -5.29 | USD 297.26M | USD 201.41M | -USD 253.58M |
| FY2023 | USD 682.00K | -USD 201.59K | -USD 139.21M | 75.5% | -3.93 | USD 381.39M | USD 137.84M | -USD 72.76M |
| FY2022 | USD 0 | -USD 197.72M | -USD 147.57M | n/a | -5.05 | USD 155.39M | USD 95.26M | -USD 74.81M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 704.62M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.18B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 556.37M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 522.72M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 466.99M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 600.16M | n/a | n/a | n/a |
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults;
Related stock research
Other Healthcare stocks
Adicet Bio Inc (1IJ)
Cartesian Therapeutics, Inc. (1S70)
QUOIN PHARMACEUT.ADR5000 (2EB0)
Aardvark Therapeutics Inc (AARD)
Abeona Therapeutics Inc (ABEO)
Acumen Pharmaceuticals Inc (ABOS)
Absci Corp (ABSI)
Arbutus Biopharma Corp (ABUS)
ABVC BioPharma Inc (ABVC)
Acadia Pharmaceuticals Inc (ACAD)
Adicet Bio Inc (ACET)
Achieve Life Sciences Inc (ACHV)
Frequently asked questions
What is Phathom Pharmaceuticals Inc's market cap?
Phathom Pharmaceuticals Inc's market capitalization is USD 704.62M.
What does Phathom Pharmaceuticals Inc do?
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.